BlackRock Inc. Invests $196.57 Million in Biohaven Ltd. $BHVN

Key Points

• BlackRock acquired 13.21 million Biohaven shares worth approximately $196.6 million, giving it an 8.77% stake. Institutional investors collectively own 88.78% of BHVN.
• Biohaven’s agreement with SK Biopharmaceuticals could provide up to $795 million in upfront and milestone payments, plus tiered royalties, while reducing development costs for its opakalim epilepsy program.
• Analyst sentiment is generally positive, with a consensus “Moderate Buy” rating and an $18.94 price target, though Biohaven recently missed quarterly EPS estimates and faces key 2026 clinical readouts.

BlackRock Inc. bought a new stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 13,210,585 shares of the company's stock, valued at approximately $196,574,000. BlackRock Inc. owned approximately 8.77% of Biohaven at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in BHVN. Janus Henderson Group PLC grew its position in shares of Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company's stock worth $148,214,000 after buying an additional 16,127,247 shares during the period. Suvretta Capital Management LLC boosted its stake in Biohaven by 83.0% during the fourth quarter. Suvretta Capital Management LLC now owns 10,286,937 shares of the company's stock worth $116,140,000 after acquiring an additional 4,666,666 shares in the last quarter. Stifel Financial Corp boosted its stake in Biohaven by 50.3% during the fourth quarter. Stifel Financial Corp now owns 9,939,856 shares of the company's stock worth $112,221,000 after acquiring an additional 3,328,506 shares in the last quarter. Infinitum Asset Management LLC grew its holdings in Biohaven by 267.6% in the fourth quarter. Infinitum Asset Management LLC now owns 6,250,000 shares of the company's stock worth $70,562,000 after purchasing an additional 4,550,000 shares during the period. Finally, State Street Corp increased its stake in Biohaven by 34.2% in the fourth quarter. State Street Corp now owns 5,716,487 shares of the company's stock valued at $64,539,000 after purchasing an additional 1,458,204 shares in the last quarter. Institutional investors and hedge funds own 88.78% of the company's stock.

Key Stories Impacting Biohaven

Here are the key news stories impacting Biohaven this week:

• Positive Sentiment: Up to $795 million in deal value: SK Biopharmaceuticals will pay Biohaven upfront and milestone payments totaling as much as $795 million, in addition to tiered royalties ranging from the mid-teens to low twenties on U.S. net sales of opakalim. The agreement improves Biohaven’s liquidity, reduces the company’s future development costs for the program and could extend its cash runway. Biohaven and SK Biopharmaceuticals licensing agreement
• Positive Sentiment: External validation of the epilepsy program: The global partnership gives SK Biopharmaceuticals commercialization rights while allowing Biohaven to retain royalty economics. Opakalim is in Phase 2/3 development for focal epilepsy, providing a significant potential value catalyst if clinical results are successful. Reuters Biohaven SK Biopharmaceuticals deal
• Positive Sentiment: Favorable legal ruling: Biohaven also received a favorable ruling in a trade-secret misappropriation lawsuit, improving its legal position and potentially supporting recovery related to the dispute. Biohaven favorable trade-secret ruling
• Neutral Sentiment: Upcoming clinical catalyst: Investors are awaiting topline results from the RISE3 trial of opakalim, expected in the second half of 2026, as well as a separate obesity-program readout. These events could determine whether the partnership’s milestone payments and future royalty opportunity are realized. Biohaven epilepsy licensing deal and obesity trial readout

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BHVN. TD Cowen reiterated a "buy" rating on shares of Biohaven in a report on Wednesday. Bank of America reaffirmed an "underperform" rating and issued a $11.00 target price (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Royal Bank Of Canada upped their price target on Biohaven from $22.00 to $23.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 11th. Needham & Company LLC set a $11.00 price target on Biohaven in a report on Monday, June 29th. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Biohaven in a research note on Tuesday, June 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $18.94.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $16.08 on Friday. The company has a current ratio of 4.73, a quick ratio of 4.73 and a debt-to-equity ratio of 21.23. The stock has a market cap of $2.43 billion, a PE ratio of -3.47 and a beta of 1.26. The stock's fifty day simple moving average is $14.79 and its two-hundred day simple moving average is $11.86. Biohaven Ltd. has a 1-year low of $7.48 and a 1-year high of $18.57.

Biohaven (NYSE:BHVN - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). As a group, analysts forecast that Biohaven Ltd. will post -3.29 EPS for the current fiscal year.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Ltd. (NYSE:BHVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source